A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF

Cystic Fibrosis Clinical Trial

— CARDS-CF  

Official title:

A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05251467
• Other study ID #: 21CS025
• Status: Recruiting
• Start date: February 28, 2022
• Est. completion date: September 30, 2023

Study information

• Verified date: January 2023
• Source: Nottingham University Hospitals NHS Trust
• Contact: Alan Smyth
• Phone: 0115 8230612
• Email: alan.smyth[@]nottingham.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Development of a new patient reported outcome measure (PROM) that will measure the daily burden of gastrointestinal symptoms over the previous 24 hour period for people with cystic fibrosis.

Description:

Development of a Patient Reported Outcome Measure (PROM) in line with FDA guidance. The PROM is intended for daily use to measure the symptom burden of gastrointestinal symptoms for people with CF over the last 24 hours. - Development of the initial conceptual framework underpinning the PROM and confirmed through a patient focus group. - Primary item (question) generation for the PROM which will then be refined through a series of interviews with people with CF. - Testing of the items through an online patient questionnaire for testing of frequency, burden and impact of the items. - Piloting testing of the draft PROM daily for 2 weeks via smartphone app. The recall period of the PROM will be gastrointestinal symptom burden over the previous 24 hours. Potential participant's will be identified through 6 UK CF care centres at Nottingham University Hospitals NHS Trust (paediatric and adult CF centres), Leeds Teaching Hospital NHS Trust, Manchester University NHS Foundation trust, Royal Brompton and Harefield NHS Foundation Trust and Kings College Hospital NHS Foundation Trust. In addition, recruitment for the survey and trialing the PROM on a smartphone app will also take place via social media and is therefore also open to people with CF from outside these CF centres.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: September 30, 2023
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• People with cystic fibrosis age 12 years and over
• Confirmed diagnosis of cystic fibrosis based on genotype or sweat chloride testing
• Capacity to consent, or to understand the requirements of the study where parental consent is required

Exclusion Criteria:

• < 12 years age
• Unable to give informed consent

Related Conditions & MeSH terms

• Cystic Fibrosis
• Digestive System Disease
• Digestive System Diseases
• Fibrosis
• Gastrointestinal Diseases
• Genetic Disease
• Genetic Diseases, Inborn
• Lung Diseases
• Pancreatic Disease
• Pancreatic Diseases
• Respiratory Tract Diseases

Intervention

Other:
• Focus group
Focus group to confirm PROM conceptual framework
• Patient interview (n = approximately 10)
Patient interviews to refine possible questions for the PROM
• Questionnaire (n = 180)
Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population

Device:
• Testing of the pilot PROM in a smartphone app (n = 100)
Daily testing of the pilot PROM in a smartphone app for 2 weeks

Locations

Country	Name	City	State
United Kingdom	Nottingham University Hospitals NHS Trust	Nottingham

Sponsors (6)

Lead Sponsor	Collaborator
Nottingham University Hospitals NHS Trust	King's College Hospital NHS Trust, Manchester University NHS Foundation Trust, Medizinische Hochschule Brandenburg Theodor Fontane, Royal Brompton & Harefield NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To develop a new patient reported outcome measure (PROM) which will measure the daily gastrointestinal symptom burden for people with CF, with a recall period of 24 hours.	Development of a new PROM following FDA guidance which will measure the daily impact and burden of gastrointestinal symptoms for people with CF. The recall period will be the previous 24 hours. The name of the PROM will be decided as part of the development process. Question development will be iterative. Floor and ceiling effects for each of the questions will be assessed. The CFAbd score will be used to assess construct validity of the newly developed PROM. This will be completed alongside the PROM on days 1 and day 14.	2 years
Secondary	Measurement of adherence to daily data capture of the PROM through a smartphone app over a 2 week period	Adherence data - Percentage of completed PROM days over the 14 day period. Percentage of completed CFabd scores on days 1 and 14. This data will be collated through the research portal feedback facility in the app.	2 years
Secondary	Attrition rate of participants	Attrition rate over the 2 weeks, define as people completing the app for two weeks (at least 10 out of 14 days) as a percentage of those initially who gave consent to take part and use the app.	2 years
Secondary	Usability of the smartphone app	Usability of the app - participant feedback via the app on days 7 and 14 to include questions of ease of data entry on the app, whether they experience any technical issues with the app and whether questions are meaningful to participants. These questions will be developed as part of the PROM development process.	2 years